ADC Therapeutics Announces Abstracts Accepted for Presentati

Presentations to highlight clinical utility of ZYNLONTA® as a single agent and in combination Oral presentation to include initial results of investigator-initiated Phase 2 study evaluating...

Related Keywords

San Francisco Bay , California , United States , China , London , City Of , United Kingdom , San Diego , Switzerland , New Jersey , Chinese , American , Loncastuximab Tesirine , Juan Pablo Alderuccio , Nicole Riley , Lausanne Biop , Mohamed Zaki , Eugenia Litz , Mitsubishi Tanabe Pharma Corporation , Drug Administration , Exchange Commission , Duration Loncastuximab Tesirine , San Diego Convention Center On , European Medicines Agency , American Society Of Hematology , Linkedin , European Commission , Company Annual Report On Form , European Union , American Society , Annual Meeting , Chief Medical Officer , Limited Duration Loncastuximab Tesirine , Refractory Follicular Lymphoma , Manchester Grand Hyatt San Diego , Grand Hall , Sustained Circulating Tumor , Refractory Diffuse Largeb Cell , Global Study , Novel Agents , Adolescent Relapsed , Refractoryb Cell Non Hodgkin Lymphoma , Prospective Therapeutic Trials , Manageable Safety Profile , Heavily Pretreated Chinese Patients , Diffuse Largeb Cell Lymphoma , Hallsg H , San Diego Convention Center , San Francisco Bay Area , Private Securities Litigation Reform Act , Swedish Orphan Biovitrum , European Economic Area , Infrastructure Investment , Jobs Act , Healthcare Royalty Management , Blue Owl , Annual Report , Markets ,